Single Patient Access (Compassionate Use) for Continued Treatment of RO7070179 for Adult Subjects With Advanced Hepatocellular Carcinoma (HCC)
Description
This is a single-patient access (also referred to as Compassionate Use) setting for a patient who has been treated and benefited from RO7070179 while participating in a clinical study of RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion. Treatment cycles will be defined as 42 (6 weeks) days.
Study Start Date
Not specified
Estimated Completion Date
Not specified
Interventions
- Drug: RO7070179
Study ID
New York University School of Medicine -- 17-01372
Status
Available
Trial ID
Study Type
Expanded Access
Trial Phase
Not Listed
Enrollment Quota
Not Listed
Sponsor
New York University School of Medicine
Inclusion Criteria
-
1. Signed Informed Consent Form
2. Ability to comply with the protocol, in the investigator's judgment
3. Diagnosis of hepatocellular carcinoma based on previous biopsy
4. Previously treated with RO7070179 and demonstrated a clinical benefit
Exclusion Criteria
- N/A
Gender
All
Ages
18 Years and older
Accepts Healthy Volunteers
Not Listed
Study Locations and Contact Information (1)
| Study Location | Distance | Name | Phone | |
|---|---|---|---|---|
| NYU Perlmutter Cancer Center - New York, New York | 50.2 miles | Jennifer Wu MD | 212-263-6485 | Jennifer.Wu@nyumc.org |
ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.